[CytoReason in Israel 21C] Israeli AI to help Pfizer develop its next drugs
CytoReason’s machine-learning platform will help the pharma giant find the fastest route to new drug targets for autoimmune diseases. Read...
Read MoreAuthor: OurCrowd
[AEYE Health in PR Newswire] UMass Medical School and AEYE Health leverage AI to help family doctors screen and refer patients with eye conditions to specialists
AEYE Health and UMass Medical School, in collaboration with UMass Memorial Health Care, are developing a system which enables family doctors to screen patients for various retinal conditions and enable timely referrals to specialists. Read more...
Read More[Argus in PR Newswire] Argus Collaborates with Microsoft to Bring End-to-End Automotive Cyber Security Cloud Solution to Vehicle Manufacturers with Microsoft Azure IoT
TEL AVIV, Israel, March 30, 2021 /PRNewswire/ — Argus Cyber Security, a global leader in automotive cyber security, has collaborated with Microsoft Azure IoT and joined the Microsoft partner network to provide vehicle manufacturers the ability to monitor, detect, and mitigate attacks in the cloud. Read more...
Read More[EMQ in The Paypers] EMQ delivers enhanced cross-border payment capabilities in Hong Kong
Global financial settlement network EMQ has announced enhancements to its cross-border payment capabilities by adding Hong Kong’s Faster Payment System (FPS) to the network. Read...
Read More[Insightec in Globes Newswire] Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer
Phoenix, AZ, March 30, 2021 (GLOBE NEWSWIRE) — The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, has announced the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy (SDT), a noninvasive drug-device combination developed by SonALAsense in collaboration with Insightec. Read more...
Read More
